Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination withCytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML)

Antisoma Research Ltd.0 个研究点目标入组 420 人开始时间: 2008年10月21日最近更新: 2012年7月17日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Antisoma Research Ltd.
入组人数: 420

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•a.) Diagnosis of AML according to WHO diagnostic criteria (at least 20% blasts in the peripheral blood or bone marrow), with FAB classification other than M3 (Acute
•Promyelocytic Leukemia), documented by bone marrow aspiration and biopsy
•performed within 14 days prior to administration of 1st dose of remission induction
•chemotherapy;
•a. Known and documented exposure to specific leukemogenic therapy of a specified nature for a non-myeloid condition.
•b. Documented diagnosis of MDS or chronic myelomonocytic leukemia (CMML) according to WHO criteria for at least 3 months prior to study entry, with prior bone marrow aspirate, biopsy and peripheral blood smear documenting MDS available to be submitted for subsequent central pathology review.
•c.) Age 18 years or older;
•d.) Eastern Cooperative Oncology Group (ECOG) performance score = 2;
•e.) Fertile sexually active patients (men and women) must use an effective method of
•contraception which must be continued throughout the study.
•f.) Women of childbearing potential must have a negative serum pregnancy test. A
•woman of childbearing potential is defined as one who is biologically capable of
•becoming pregnant. This includes women who are using contraceptives or whose
•sexual partners are either sterile or using contraceptives;
•g.) Left Ventricular Ejection Fraction (LVEF) = 50%, as determined by multiple-gated
•acquisition scan (MUGA) or echocardiogram (ECHO) within 14 days prior to
•administration of 1st dose of remission induction chemotherapy;
•h.) Adequate renal function as evidenced by the following laboratory test, obtained
•within 14 days prior to administration of 1st dose of remission induction
•chemotherapy:
•Serum creatinine = 1.5 x ULN;
•i.) Adequate hepatic function as evidenced by the following laboratory tests, obtained within 14 days prior to administration of 1st dose of remission induction
•chemotherapy (unless attributed to hepatic involvement with AML):
•Total serum bilirubin = 1.5 x ULN;
•Serum AST and ALT = 1.5 x ULN;
•j.) Ability of the patient to participate fully in all aspects of this clinical trial;
•k.) Written Informed Consent and HIPAA authorization (USA sites only) must be
•obtained and documented.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•a.) Histologic diagnosis of FAB M3 Acute Promyelocytic Leukemia;
•b.) Clinically active CNS leukemia;
•c.) Prior induction therapy for AML;
•d.) Known HIV positive;
•e.) Known active hepatitis B or C, or any other active liver disease;
•f.) Patients with parenchymal abnormality on screening chest x-ray must have no
•evidence of pulmonary infection on chest tomography (CT) prior to starting remission
•induction therapy.
•g.) Any major surgery or radiation therapy within 4 weeks prior to study entry;
•h.) Prior cytotoxic chemotherapy for MDS within 4 weeks prior to study entry (patients with rapidly rising blast count may be enrolled within 4 weeks of prior cytotoxic chemotherapy with waiver from the Medical Monitor);
•i.) Persistent chronic non-hematologic toxicity (other than alopecia) greater than grade 1 from prior therapy for MDS;
•j.) Serious concomitant illnesses (for example, pulmonary infiltrate, unstable angina or myocardial infarction or stroke within 3 months prior to study entry, congestive heart failure AHA class 2 or greater, uncontrolled hypertension, uncontrolled diabetes, actively bleeding gastric ulcer, etc.), which in the investigator’s opinion would not make the patient a good candidate for the trial;
•k.) Pregnant or breast feeding;
•l.) History of clinically significant allergic reactions attributed to compounds of similar
•chemical or biological composition to amonafide, cytarabine or daunorubicin;
•m.) Prior enrollment in this trial;
•n.) Any other known condition (e.g., familial, sociological, or geographical) or behavior
•(including substance dependence or abuse, psychological or psychiatric illness), which in the investigator’s opinion would make the patient a poor candidate for the

研究者

发起方

Antisoma Research Ltd.

相似试验

进行中（未招募）

1 期

Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination withCytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML) - ACCEDEsecondary acute myeloid leukemiaMedDRA version: 9.1Level: LLTClassification code 10000886Term: Acute myeloid leukemia

EUCTR2007-004427-38-CZAntisoma Research Ltd.420

进行中（未招募）

不适用

Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination withCytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML)

EUCTR2007-004427-38-GRAntisoma Research Ltd.420

进行中（未招募）

不适用

EUCTR2007-004427-38-ITANTISOMA420

进行中（未招募）

不适用

EUCTR2007-004427-38-BEAntisoma Research Ltd.420

进行中（未招募）

不适用

EUCTR2007-004427-38-DEAntisoma Research Ltd.420